The Food and Drug Administration today released a plan to improve medical device safety. The plan calls for increased funding to develop an active surveillance capability for FDA’s National Evaluation System for health Technology (NEST) and conduct post-market studies to evaluate specific safety concerns. The agency also will explore ways to streamline post-market safety mitigations; spur innovation towards safer medical devices; advance device cybersecurity; and integrate its activities to promote safety across the product lifecycle. With respect to cybersecurity, the agency plans to update premarket guidance to better protect against risks such as ransomware campaigns and vulnerabilities that could enable a remote multi-patient attack. It also will consider requiring firms to build into a product’s design the ability to update and patch device security and provide a “software bill of materials” listing software embedded in a device, and developing a CyberMed Safety Analysis Board to serve as a resource to device makers and FDA. The agency is accepting comments on the plan at https://www.regulations.gov.

Related News Articles

Headline
The Cybersecurity and Infrastructure Security Agency, National Security Agency and international agencies Sept. 3 released joint guidance outlining a “software…
Headline
The Food and Drug Administration has identified Class I recalls for the following products due to the potential for serious injury or death:Certain lots of…
Headline
Chinese state-sponsored cyber actors are maliciously targeting networks globally, including telecommunications, government and others, according to a joint…
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…
Headline
The AHA Quest for Quality Prize honors hospitals and health systems committed to leadership and innovation in improving quality and advancing health. Learn how…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…